Caixin Deep Dive: How AstraZeneca’s China Fraud Was About More Than Greed
China Business Insider - News From Caixin Global
Release Date: 11/08/2024
Caixin Deep Dive: Overhaul of Chinese Insurers’ Accounting Rules
China Business Insider - News From Caixin Global
Chinese insurers face increased volatility in key financial metrics as they adopt international accounting standards aimed at enhancing transparency Note: The conversation segment of this episode was generated using AI and has been edited for accuracy. It is based on a Caixin story: Subscribe now to unlock all coverage from Caixin Global and The Wall Street Journal for just $200 a year, enjoying a . Group discounts are available — contact us for a .
info_outline
Caixin Deep Dive: How BMW, Audi and Mercedes Ended Up Also-Rans in China
China Business Insider - News From Caixin Global
The German auto giants were late to adapt to the shift to EVs and failed to recognize how competitive the Chinese market had become, industry insiders say Note: The conversation segment of this episode was generated using AI and has been edited for accuracy. It is based on a Caixin story: Subscribe now to unlock all coverage from Caixin Global and The Wall Street Journal for just $200 a year, enjoying a . Group discounts are available — contact us for a .
info_outline
Caixin Deep Dive: How AstraZeneca’s China Fraud Was About More Than Greed
China Business Insider - News From Caixin Global
The British pharmaceutical giant falsified patient test results to secure insurance coverage for its cancer drug in an effort to boost sales, but the alleged misconduct ended up benefiting some patients. Note: The conversation segment of this episode was generated using AI and has been edited for accuracy. It is based on a Caixin story: Subscribe now to unlock all coverage from Caixin Global and The Wall Street Journal for just $200 a year, enjoying a . Group discounts are available — contact us for a .
info_outline
Caixin Deep Dive: State Investors’ Desire for Quick Buck Undermines China’s Push for ‘Patient Capital’
China Business Insider - News From Caixin Global
Exploring the drive for quick returns among China’s state investors and how it contrasts with the country’s push for long-term investment in high-tech. Note: The conversation segment of this episode was generated using AI and has been edited for accuracy. It is based on a Caixin story: Subscribe now to unlock all coverage from Caixin Global and The Wall Street Journal for just $200 a year, enjoying a . Group discounts are available — contact us for a .
info_outline
Caixin Deep Dive: China’s Economy at a Crossroads
China Business Insider - News From Caixin Global
Breaking down the country’s third-quarter GDP growth and what comes next. Note: The conversation segment of this episode was generated using AI and has been edited for accuracy. It is based on a Caixin story: Subscribe now to unlock all coverage from Caixin Global and The Wall Street Journal for just $200 a year, enjoying a . Group discounts are available — contact us for a .
info_outline
Caixin Deep Dive: China’s Fiscal and Monetary Stimulus Combo
China Business Insider - News From Caixin Global
The impact of Beijing’s two-pronged approach on the country’s economic fundamentals remains to be seen. Note: The conversation segment of this episode was generated using AI and has been edited for accuracy. It is based on two Caixin stories: Subscribe to a bundle deal now to unlock all coverage by Caixin Global and The Wall Street Journal for only $200 a year. . Group access and applicable discounts are available. .
info_outline
Caixin Deep Dive: How Chinese Investment Guru’s ‘Supernatural’ Predictions Failed His Followers
China Business Insider - News From Caixin Global
. His company’s 2018 gala even featured former national leaders like Nicolas Sarkozy and Kevin Rudd. But now, investors are left waiting to get their money back. The conversation segment of this episode was generated using AI and has been edited for accuracy. It is based on a Caixin article: Subscribe to a bundle deal now to unlock all coverage by Caixin Global and The Wall Street Journal for only $200 a year. . Group access and applicable discounts are available. .
info_outline
Caixin Deep Dive: PwC China’s Record Penalty
China Business Insider - News From Caixin Global
Notes: For brevity, “PwC China” in this podcast refers to PwC’s Chinese mainland affiliate, PwC Zhong Tian LLP. Likewise, “Evergrande” refers to the primary mainland subsidiary of China Evergrande Group, Hengda Real Estate Group Co. Ltd. The conversation segment of this podcast was generated using AI and has been edited for accuracy. It is based on a . Subscribe to a bundle deal now to unlock all coverage by Caixin Global and The Wall Street Journal for only $200 a year. . Group access and applicable discounts are available. .
info_outline
Caixin Biz Roundup: Indonesia Woos Chinese Investment in Solar, EV Battery Production
China Business Insider - News From Caixin Global
Beijing to launch anti-discrimination probe after Canada hikes EV tariffs, Mercedes-Benz plans $2 billion joint investment in China to regain lost ground. Subscribe to a bundle deal now to unlock all coverage by Caixin Global and The Wall Street Journal for only $200 a year. . Group access and applicable discounts are available. .
info_outline
Caixin Biz Roundup: Chinese Localities ‘Sell Everything to Save the Day’
China Business Insider - News From Caixin Global
EV-maker BYD to buy out its German distributor, China Vanke debt cracks exposed after first loss in 20 years. Subscribe to a bundle deal now to unlock all coverage by Caixin Global and The Wall Street Journal for only $200 a year. . Group access and applicable discounts are available. .
info_outlineThe British pharmaceutical giant falsified patient test results to secure insurance coverage for its cancer drug in an effort to boost sales, but the alleged misconduct ended up benefiting some patients.
Note: The conversation segment of this episode was generated using AI and has been edited for accuracy. It is based on a Caixin story:
Cover Story: How AstraZeneca’s China Fraud Was About More Than Greed
Subscribe now to unlock all coverage from Caixin Global and The Wall Street Journal for just $200 a year, enjoying a 66% discount. Group discounts are available — contact us for a customized plan.